In vitro 5-Fluorouracil resistance produces enhanced photodynamic therapy damage in SCC and tumor resistance in BCC

J Photochem Photobiol B. 2022 Aug:233:112483. doi: 10.1016/j.jphotobiol.2022.112483. Epub 2022 May 29.

Abstract

Non-melanoma skin cancer (NMSC) is the most common malignancy worldwide, with rising incidence in the recent years. It includes basal cell carcinoma (BCC), and squamous cell carcinoma (SCC). Several non-invasive therapies have been developed for its treatment such as topical 5-Fluorouracil (5FU) and photodynamic therapy (PDT), among others. Despite both are appropriated for NMSC treatment, recurrence cases have been reported. To prevent this, in this work we explore the potential of the combination of PDT and 5FU to treat SCC and BCC. First we evaluate the efficacy of PDT in cells resistant to 5FU. For this purpose, we use SCC-13 and CSZ-1 cells, obtained from a human SCC and a murine BCC, respectively. We first induced 5FU resistance in these cell lines by repeated treatments with the drug and then, the efficacy to PDT was evaluated. The results obtained indicated that SCC-5FU resistant cells were sensible to PDT administration, whereas BCC-5FU resistant cells were also resistant to PDT. The observed responses in both cell lines are in concordance to Protoporphyrin IX (PpIX) and reactive oxygen species (ROS) levels produced after the incubation with MAL and subsequent light exposure. The obtained data support the fact that PDT seems to be an appropriate therapeutic option to be administered after 5FU resistance in SCC. However, PDT would not be a choice therapy for resistant BCC cells to 5FU.

Keywords: 5-Fluorouracil; Non-melanoma skin cancer; Photodynamic therapy; Protoporphyrin IX; Tumor resistance.

MeSH terms

  • Aminolevulinic Acid / pharmacology
  • Animals
  • Carcinoma, Basal Cell* / drug therapy
  • Carcinoma, Squamous Cell* / pathology
  • Fluorouracil / pharmacology
  • Fluorouracil / therapeutic use
  • Humans
  • Mice
  • Photochemotherapy* / methods
  • Photosensitizing Agents / pharmacology
  • Photosensitizing Agents / therapeutic use
  • Skin Neoplasms* / etiology

Substances

  • Photosensitizing Agents
  • Aminolevulinic Acid
  • Fluorouracil